JPRN-UMIN000018520已完成4 期
Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension - Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension
Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine0 个研究点目标入组 60 人开始时间: 2016年1月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patient who is scheduled for PEA and/or BPA. 2)Newly initiation of soluble guanylate cyclase stimulator 3)Recent induction of homeoxygen therapy 4)Contraindication for edoxaban 5)High risk patients of bleeding 6)Past history of alveolar hemorrhage 7)cCr<30mL/min 8)Patients who taking more than 2 antiplatelet drugs 9)pregnant/lactating woman
研究者
相似试验
已完成
不适用
Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver diseasePortal vein thrombosisJPRN-UMIN000030108Kanazawa University Hospital20
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2016-002683-14-NLDaiichi Sankyo Europe GmbH1,506
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.EUCTR2016-002683-14-ATDaiichi Sankyo Europe GmbH1,500
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.EUCTR2016-002683-14-LTDaiichi Sankyo Europe GmbH1,500
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.Subjects with atrial fibrillation (AF) following successful PCI with stent placement.MedDRA version: 20.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2016-002683-14-IEDaiichi Sankyo Europe GmbH1,500